Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  BULGARIAN STOCK EXCHANGE  >  Sopharma AD    3JR   BG11SOSOBT18

SOPHARMA AD (3JR)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (BGN)
Sales 2018 1 195 M
EBIT 2018 58,5 M
Net income 2018 -
Debt 2018 -
Yield 2018 3,07%
Sales 2019 1 304 M
EBIT 2019 61,6 M
Net income 2019 -
Debt 2019 -
Yield 2019 2,46%
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0,44x
Capi. / Sales2019 0,41x
Capitalization 531 M
More Financials
Company
Sopharma AD engages in the provision of pharmaceutical business.Its operations include production and marketing of medical products, medicinal substances as well as dosage forms.It also involved in research, engineering, and implementation activities in the field of phytochemistry, chemistry, and... 
More about the company
Latest news on SOPHARMA AD
05/03SOPHARMA : Publication of invitation and materials for AGM
PU
03/07ACHIEVE LIFE SCIENCES : Announces Recent Highlights and Reports Year-End 2017 Fi..
AQ
03/01GLOBAL CONTRACT PHARMACEUTICAL MANUF : 99strategy added a depth and professional..
AQ
2016SOPHARMA AD : Notification
PU
2016SOPHARMA AD : Press release
PU
2016SOPHARMA AD : Press Release
PU
2016SOPHARMA AD SOFIA : Press Relsease
PU
2016SOPHARMA AD SOFIA : Press release
PU
2012SOPHARMA AD SOFIA : Sopharma donates medicines for charity action
PU
2012SOPHARMA AD SOFIA : Fitness Center for the workers and employees of Sopharma AD
PU
More news
Sector news : Drug Retailers - NEC
07/12CVS HEALTH : U.S. DoJ will not challenge Aetna-CVS deal
RE
07/05WALGREENS BOOTS ALLIANCE : Closes Buy of 40% Stake in Chinese Pharmacy Chain Guo..
DJ
07/02Health Care Flat as Amazon Move Seen Shaking Up Pharmacy Business -- Health C..
DJ
06/29Amazon Shakes Up Pharmacy Business -- WSJ
DJ
06/28McKesson Down 44.06% From May 2015 All-Time High -- Data Talk
DJ
More sector news : Drug Retailers - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,36  BGN
Spread / Average Target 32%
Managers
NameTitle
Ognian Ivanov Donev Chairman, CEO, MD & Executive Director
Boris Anchev Borisov Chief Financial Officer
Iliyan Slavov Kolev Director-Technical Matters
Vessela Liubenova Stoeva Deputy Chairman
Ognyan Kirilov Palaveev Director
Sector and Competitors
1st jan.Capitalization (M$)
SOPHARMA AD317
CVS HEALTH CORPORATION-9.99%67 241
WALGREENS BOOTS ALLIANCE-10.52%64 437
EXPRESS SCRIPTS HOLDING CO3.91%43 101
MCKESSON CORPORATION-14.78%27 000
AMERISOURCEBERGEN-7.75%18 806